MAPT and Alzheimer disease: Measurements of plasma tau phosphorylated at residues 181 and 217 (p-tau181 and p-tau217) in particular have shown that these tau species have remarkable accuracy as candidate biomarkers of AD diagnosis and progression, both in CSF [51–55] and plasma [56–67].